Login to Your Account

4Catalyzer goes on the 'LAM' to treat rare lung disease, cancer

By Marie Powers
News Editor

Wednesday, February 3, 2016

LAM Therapeutics, a portfolio company of Connecticut biotech start-up incubator 4Catalyzer, closed a $40 million financing to advance lead programs, LAM-001, an inhaled mTOR kinase Inhibitor in phase I development to treat lymphangioleiomyomatosis – also known as LAM lung disease – and LAM-002, a selective kinase inhibitor that is cytotoxic for certain cancers with little or no effect on normal cells.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription